2. Academic Validation
  3. An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development

An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development

  • Expert Opin Pharmacother. 2021 Dec;22(17):2359-2371. doi: 10.1080/14656566.2021.1951224.
Soledad Retamozo 1 2,  Antoni Sisó-Almirall 3 4,  Alejandra Flores-Chávez 5,  Manuel Ramos-Casals 1 5,  Pilar Brito-Zerón 5 6
Affiliations

Affiliations

  • 1 Sjogren Syndrome Research Group (AGAUR), Department of Autoinmune Diseases, ICMiD, Hospital Clinic, Barcelona, Spain.
  • 2 Rheumatology Department, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain.
  • 3 Primary Care Centre Les Corts, Consorci d'Atenció Primària De Salut Barcelona Esquerra (CAPSBE), Barcelona, Spain.
  • 4 Primary Healthcare Transversal Research Group, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
  • 5 Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain.
  • 6 Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA-Sanitas, Barcelona, Spain.
PMID: 34323636 DOI: 10.1080/14656566.2021.1951224
Abstract

Introduction: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that may affect 3 in 1,000 people within the general population. The therapeutic scenario is complex, and no therapy has proved to be able to modify the natural course of the disease, nor to prevent the most severe systemic complications.Areas covered: Recently, the EULAR 2020 Recommendations for pSS have underlined the low level of evidence supporting efficacious therapeutic approaches, lacking a definition of specific treatment targets and being far from the 'disease modification' concept that is frequently used in Other Diseases. Herein, the authors review the status of current targeted therapies and provide the reader with their expert opinion.Expert opinion: The progress in discovering novel treatments for pSS seem to be focused on searching new biological therapies as highly-selective drugs that can be effective without the adverse effects related to the wide, nonspecific immunosuppression induced by the drugs currently used. Most likely, the more disruptive therapeutic approach in pSS that could be seen in a few years is the use of combination strategies targeting different etiopathogenic pathways.

Keywords

Primary sjögren syndrome; abatacept; anakinra; b cell activating factor receptor-blocking; baminercept; phosphatidylinositol 3-kinase delta inhibitor; rituximab; targets cd40; tocilizumab.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z